History | Ranibizumab for treating diabetic macular oedema | Guidance | NICE

History

A list of downloadable documents created during development.

Background information

TA274 Macular oedema (diabetic) - ranibizumab: review decision - April 2015 information
TA274 Macular oedema (diabetic) - ranibizumab: appendix A - GE decision paper - March 2015 ^{PDF 68 KB} 10 April 2015
TA274 Macular oedema (diabetic) - ranibizumab: review proposal - February 2015 information
TA274 Macular oedema (diabetic) - ranibizumab: appendix A - GE proposal paper February 2015 ^{PDF 500 KB} 23 February 2015
TA274 Macular oedema (diabetic) - ranibizumab: appendix A - matrix of stakeholders ^{PDF 41 KB} 23 February 2015
TA274 Macular oedema (diabetic) - ranibizumab: press release information
NICE Single Technology Appraisal process guide ^{PDF 286 KB} 06 December 2013

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): equality impact assessment - guidance development

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): equality impact assessment - guidance development ^{PDF 18 KB} 02 July 2013

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): final appraisal determination

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): final appraisal determination information
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): final appraisal determination guidance ^{PDF 278 KB} 04 January 2013
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) ^{PDF 138 KB} 04 January 2013
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): consultee and commentator comments on the ACD
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Novartis ^{PDF 189 KB} 04 January 2013
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Diabetes UK ^{PDF 67 KB} 04 January 2013
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): RNIB ^{PDF 28 KB} 04 January 2013
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): RCP and ABCD ^{PDF 14 KB} 04 January 2013
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): CSAS ^{PDF 108 KB} 04 January 2013
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Department of Health ^{PDF 8.3 KB} 04 January 2013
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): comments on the ACD received from the public through the NICE website ^{PDF 83 KB} 04 January 2013

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): appraisal consultation

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): appraisal consultation
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): appraisal consultation document information
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): evaluation report
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): pre-meeting briefing ^{PDF 86 KB} 05 October 2012
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Evidence Review Group report for NICE rapid review ^{PDF 319 KB} 05 October 2012
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Novartis ^{PDF 299 KB} 05 October 2012

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): final scope

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): final scope ^{PDF 28 KB} 05 October 2012